-
A mitochondrial-derived peptide studied for AMPK activation, mitochondrial biogenesis, and metabolic flexibility. Evaluated for its effect on insulin sensitivity and fatigue resistance. -
GHRH analog studied for lipolytic activity, particularly targeting visceral fat. Originally developed for HIV-associated lipodystrophy. -
Combination studied for enhanced regenerative effects, particularly in muscle, tendon, and ligament recovery models. Shows synergistic influence on cellular migration and healing. -
An amylin receptor agonist under research for its effects on appetite regulation and body weight management in combination with GLP-1 receptor agonists. -
Triple agonist (GLP-1/GIP/Glucagon) under investigation for weight management and metabolic optimization. Animal studies show enhanced fat oxidation and energy expenditure. -
Dual GIP and GLP-1 receptor agonist studied for glycemic control and weight loss. Demonstrates superior metabolic improvements in rodent and primate models. -
A synthetic tetrapeptide derived from the pineal gland peptide epithalamin. Research focuses on its telomerase activation and potential cellular aging regulation. -
Triple-combo formulation studied for advanced regenerative applications. Focus areas include dermal rejuvenation, soft tissue repair, and anti-inflammatory response. -
Investigated for its senolytic properties, this peptide disrupts FOXO4–p53 interactions to promote apoptosis in senescent cells, targeting aging and tissue regeneration pathways. -
Comprehensive recovery peptide stack investigated for multi-pathway support of inflammation control, collagen regeneration, and mucosal healing. -
Also known as Elamipretide, a mitochondrial-targeting peptide evaluated for restoring cardiolipin integrity, reducing ROS, and improving ATP output in mitochondrial dysfunction.
Complimentary Upgrade to 2-Day Shipping on Orders Over $300 | Pay for standard — we’ll handle the upgrade.
You must be logged in to post a comment.